Hvivo (HVO)

Sector:

Health Care

Index:

FTSE AIM All-Share

8.70p
   
  • Change Today:
    -7.50p
  • 52 Week High: 30.60p
  • 52 Week Low: 6.50p
  • Currency: UK Pounds
  • Shares Issued: 687.01m
  • Volume: 83,112,085
  • Market Cap: £59.77m

hVIVO manufactures human challenge agent for Omicron

By Josh White

Date: Thursday 16 Mar 2023

LONDON (ShareCast) - (Sharecast News) - Specialist contract research organisation hVIVO has successfully manufactured its Omicron human challenge agent, it announced on Thursday.
The AIM-traded firm said the development expanded its portfolio to 11 human challenge models, for testing a broad range of infectious and respiratory disease products.

It said it was now actively offering Omicron human challenge trials as part of its service offering, and was in discussions with a number of existing and potential customers.

The board said the Omicron human challenge agent was developed with Vaxart, with the intent to conduct a subsequent Omicron human challenge study to test the efficacy of Vaxart's oral vaccine candidate.

However, Vaxart had announced its decision to postpone further clinical trials in its Covid-19 programme, including the challenge study, as it focussed on the development of an oral pan-betacoronavirus vaccine that could provide improved protection against SARS-CoV-2 and other types of betacoronaviruses.

"The Vaxart challenge study was not included in the company's order book and its postponement will have no impact on hVIVO's 2023 financial guidance," the board said in its statement.

"As at 31 December, the company's order book was £76m, with over 95% of forecasted revenue for 2023 contracted."

At the close on Thursday, shares in hVIVO were up 0.88% at 17.25p.

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Hvivo Market Data

Currency UK Pounds
Share Price 8.70p
Change Today -7.50p
% Change -46.30 %
52 Week High 30.60p
52 Week Low 6.50p
Volume 83,112,085
Shares Issued 687.01m
Market Cap £59.77m

Hvivo Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
39.06% above the market average39.06% above the market average39.06% above the market average39.06% above the market average39.06% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Price Trend
84.79% below the market average84.79% below the market average84.79% below the market average84.79% below the market average84.79% below the market average
62.16% below the sector average62.16% below the sector average62.16% below the sector average62.16% below the sector average62.16% below the sector average
Income
8.77% above the market average8.77% above the market average8.77% above the market average8.77% above the market average8.77% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Growth
65.02% above the market average65.02% above the market average65.02% above the market average65.02% above the market average65.02% above the market average
14.29% below the sector average14.29% below the sector average14.29% below the sector average14.29% below the sector average14.29% below the sector average

What The Brokers Say

Strong Buy 3
Buy 4
Neutral 0
Sell 0
Strong Sell 0
Total 7
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Hvivo Dividends

  Latest Previous
  Final Final
Ex-Div 15-May-25 18-Apr-24
Paid 11-Jun-25 20-May-24
Amount 0.20p 0.20p

Trades for 30-May-2025

Time Volume / Share Price
16:37 36,000 @ 8.70p
16:35 62,515 @ 8.70p
16:35 6,570 @ 8.70p
16:35 15,404 @ 8.70p
16:35 40,541 @ 8.70p

Hvivo Key Personnel

CEO Yamin Mo' Khan

Top of Page